"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
| Descriptor ID |
D016219
|
| MeSH Number(s) |
E02.095.465.425.400.330.050.400 E05.478.550.520.050.400
|
| Concept/Terms |
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in this website by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 3 | 4 |
| 2003 | 2 | 4 | 6 |
| 2004 | 2 | 4 | 6 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 2 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 2 | 3 |
| 2010 | 4 | 2 | 6 |
| 2011 | 1 | 1 | 2 |
| 2012 | 3 | 2 | 5 |
| 2013 | 5 | 0 | 5 |
| 2014 | 3 | 1 | 4 |
| 2015 | 4 | 2 | 6 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 7 | 1 | 8 |
| 2019 | 6 | 2 | 8 |
| 2020 | 6 | 1 | 7 |
| 2021 | 15 | 2 | 17 |
| 2022 | 2 | 15 | 17 |
| 2023 | 3 | 12 | 15 |
| 2024 | 15 | 8 | 23 |
| 2025 | 36 | 5 | 41 |
| 2026 | 21 | 1 | 22 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma. N Engl J Med. 2026 Sep 24; 395(12):1180-1192.
-
Late cytopenia after CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a Cell Therapy Consortium analysis. Blood Adv. 2026 09 22; 10(18):6188-6197.
-
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood Adv. 2026 09 08; 10(17):5778-5788.
-
CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study. Lancet Haematol. 2026 Sep; 13(9):e648-e659.
-
Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study. Blood. 2026 08 06; 148(6):657-668.
-
Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy. Cancer Immunol Res. 2026 Aug 04; 14(8):1292-1306.
-
Tumor-infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions. Cancer. 2026 Aug 01; 132(15):e70526.
-
Geographic Variation and Inequities in Burden and Access to CAR T-Cell Therapies for Multiple Myeloma in the US. Clin Lymphoma Myeloma Leuk. 2026 Oct; 26(10):e1202-e1210.e8.
-
Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Leukemia. 2026 Oct; 40(10):2181-2190.
-
CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study. Cancer Res Commun. 2026 07 01; 6(7):1681-1692.